Beginning in April, California and New York will join a growing list of states that have opted to carve out prescription drug benefits from their Medicaid contracts with insurers, wagering that the state can do a better job at negotiating drug prices with manufacturers than managed care organizations and their contracted PBMs.
To access this post, you must purchase a subscription plan. Click Here to purchase.

Already a member? Click Here to login.